Maharashtra Herald

Chronic Hepatitis C Virus Infection Pipeline, Clinical Trials Analysis, FDA Approvals 2023 | Major Companies – PharmaEssentia, AbbVie, Alios BioPharma, Merck and Co, TaiGen Biotechnology, and Others

 Breaking News
  • No posts were found

Chronic Hepatitis C Virus Infection Pipeline, Clinical Trials Analysis, FDA Approvals 2023 | Major Companies – PharmaEssentia, AbbVie, Alios BioPharma, Merck and Co, TaiGen Biotechnology, and Others

May 18
20:06 2023
Chronic Hepatitis C Virus Infection Pipeline, Clinical Trials Analysis, FDA Approvals 2023 | Major Companies - PharmaEssentia, AbbVie, Alios BioPharma, Merck and Co, TaiGen Biotechnology, and Others

DelveInsight’s, “Chronic Hepatitis C Virus Infection Pipeline Insight 2023” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Hepatitis C Virus Infection pipeline landscape. It covers the Chronic Hepatitis C Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Hepatitis C Virus Infection Pipeline Report

 

  • DelveInsight’s Chronic Hepatitis C Virus Infection Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Chronic Hepatitis C Virus Infection treatment.

 

  • The leading Chronic Hepatitis C Virus Infection Companies include GeneCure Biotechnologies, Sunshine Lake Pharma Co., Ltd., PharmaEssentia, AbbVie, COCRYSTAL PHARMA, INC., TaiGen Biotechnology Co., Ltd., Alios BioPharma, Merck and Co, TaiGen Biotechnology Co., Ltd., and others

 

  • Promising Chronic Hepatitis C Virus Infection Pipeline Therapies include Ribavirin, Telaprevir, Pegylated interferon alfa-2a, ABT-493/ABT-530, sofosbuvir (SOF), Dasabuvir, SOF/VEL, and others

 

  • The Chronic Hepatitis C Virus Infection companies and academics that are working to assess challenges and seek opportunities that could influence Chronic Hepatitis C Virus Infection R&D. The Chronic Hepatitis C Virus Infection therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Request a sample and discover the recent breakthroughs happening in the Chronic Hepatitis C Virus Infection Pipeline Landscape @ Chronic Hepatitis C Virus Infection Pipeline Outlook

 

Chronic Hepatitis C Virus Infection Overview

Hepatitis C is a viral infection that causes liver inflammation and damage. Inflammation is swelling that occurs when tissues of the body become injured or infected. Inflammation can damage organs. Hepatitis C can cause an acute or chronic infection. Chronic hepatitis C is a long-lasting infection. Chronic hepatitis C occurs when your body isn’t able to fight off the virus.

 

Chronic Hepatitis C Virus Infection Emerging Drugs

 

  • HCVax: GeneCure Biotechnologies

HCVax is being developed by GeneCure Biotechnologies to treat patients suffering from Chronic Hepatitis C Infection. The company is conducting a Phase I trial to evaluate the safety and the immune responses of a lentiviral based HCV immunotherapy (HCVax™) in chronic HCV patients.

 

  • HEC 74647PA: Sunshine Lake Pharma Co., Ltd.

HEC 74647PA is being developed by Sunshine Lake Pharma Co., Ltd. to treat patients suffering from Chronic Hepatitis C Infection. The company is conducting a Phase II/III Study to Evaluate Efficacy and Safety of Antaitavir Hasophate Capsules in Combination with Yiqibuvir Tablets in Adult Subject with Chronic HCV Infection.

 

For further information, refer to the detailed Chronic Hepatitis C Virus Infection Drugs Launch, Chronic Hepatitis C Virus Infection Developmental Activities, and Chronic Hepatitis C Virus Infection News, click here for Chronic Hepatitis C Virus Infection Ongoing Clinical Trial Analysis

 

Chronic Hepatitis C Virus Infection Pipeline Therapeutics Assessment

There are approx. 8+ key companies which are developing the therapies for Chronic Hepatitis C Virus Infection. The companies which have their Chronic Hepatitis C Virus Infection drug candidates in the most advanced stage, i.e. phase II/III include, Sunshine Lake Pharma Co., Ltd.

 

Chronic Hepatitis C Virus Infection Segmentation: Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Chronic Hepatitis C Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Find out more about the Chronic Hepatitis C Virus Infection Pipeline Segmentation, Therapeutics Assessment, and Chronic Hepatitis C Virus Infection Emerging Drugs @ Chronic Hepatitis C Virus Infection Treatment Landscape

 

Scope of the Chronic Hepatitis C Virus Infection Pipeline Report

 

  • Coverage- Global

 

  • Chronic Hepatitis C Virus Infection Companies- GeneCure Biotechnologies, Sunshine Lake Pharma Co., Ltd., PharmaEssentia, AbbVie, COCRYSTAL PHARMA, INC., TaiGen Biotechnology Co., Ltd., Alios BioPharma, Merck and Co, TaiGen Biotechnology Co., Ltd., and others

 

  • Chronic Hepatitis C Virus Infection Pipeline Therapies- Ribavirin, Telaprevir, Pegylated interferon alfa-2a, ABT-493/ABT-530, sofosbuvir (SOF), Dasabuvir, SOF/VEL, and others

 

  • Chronic Hepatitis C Virus Infection Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Chronic Hepatitis C Virus Infection Pipeline Companies and Therapies, click here @ Chronic Hepatitis C Virus Infection Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Hepatitis C Virus Infection: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Hepatitis C Virus Infection – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II/III)
  11. HEC 74647PA: Sunshine Lake Pharma Co., Ltd.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. HCVax: GeneCure Biotechnologies
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Hepatitis C Virus Infection Key Companies
  21. Chronic Hepatitis C Virus Infection Key Products
  22. Chronic Hepatitis C Virus Infection- Unmet Needs
  23. Chronic Hepatitis C Virus Infection- Market Drivers and Barriers
  24. Chronic Hepatitis C Virus Infection- Future Perspectives and Conclusion
  25. Chronic Hepatitis C Virus Infection Analyst Views
  26. Chronic Hepatitis C Virus Infection Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Chronic Hepatitis C Virus Infection Mergers and acquisitions, Chronic Hepatitis C Virus Infection Licensing Activities @ Chronic Hepatitis C Virus Infection Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/